Jagged2-Expressing Hematopoietic Progenitors Promote Regulatory T Cell Expansion in the Periphery through Notch Signaling  by Kared, Hassen et al.
Immunity 25, 823–834, November 2006 ª2006 Elsevier Inc. DOI 10.1016/j.immuni.2006.09.008Jagged2-Expressing Hematopoietic Progenitors
Promote Regulatory T Cell Expansion
in the Periphery through Notch SignalingHassen Kared,1,2 Homa Adle-Biassette,3 Elena Foı¨s,2
Annie Masson,2 Jean-Franc¸ois Bach,2
Lucienne Chatenoud,2 Elke Schneider,1
and Flora Zavala1,2,*
1Centre National de la Recherche Scientifique CNRS
UMR 8147
Universite´ Paris V Rene´ Descartes
Necker Institute
75743 Paris Cedex 15
France
2 Institut National de la Sante´ et de la Recherche
Me´dicale INSERM U580
Necker Institute








Cellular interactions promoting the in vivo expansion
of CD4+CD25+Foxp3+ regulatory T (Treg) cells for
maintenance of immune tolerance remain poorly de-
fined. Here we report that mobilized Lin2Sca-1+c-kit+
(LSK) hematopoietic progenitor cells (HPCs), unlike
medullary hematopoietic stem cells (HSCs), selec-
tively drove the direct, immediate expansion of func-
tional host-derived Treg cells, thereby preventing the
progression to overt spontaneous autoimmune diabe-
tes in nonobese diabetic mice. Treg cell expansion re-
quired cell-to-cell contact andNotch3 signaling, which
was mediated selectively through the Notch ligand
Jagged2 expressed by the multipotent HPC subset,
as assessed by small interfering RNA (siRNA) silenc-
ing. Conversely, notwithstanding their similar multili-
neage microchimerism, neither sorted Jagged22 HPCs
nor Jagged2lo medullary HSCs were able to expand
Treg cells. These data provide evidence for a produc-
tive Notch-mediated interaction between a unique
subset of mobilized hematopoietic progenitors and
Treg cells. They open therapeutic perspectives for au-
tologous transplantation of Jagged2+ LSKprogenitors
to promote Treg cell expansion in T cell-mediated
diseases.
Introduction
Regulatory T (Treg) cell subsets, such as the
CD4+CD25+Foxp3+ T cells play a major role in the con-
trol of immunologic self-tolerance and progression
toward autoimmune disease onset (Sakaguchi, 2004).
Ever since therapy with in vitro expanded Treg cells
has been envisaged as a promising means of immunoin-
*Correspondence: zavala@necker.frtervention, a number of investigators (Bluestone and
Tang, 2004) have actively sought for efficient expansion
of this regulatory subset for therapeutic usage. Even
though Treg cells readily expand in lymphopenic mice
(Gavin et al., 2002), the molecular and cellular interac-
tions responsible for their stable and effective in vivo
development in nonlymphopenic settings, particularly
during the period that immediately precedes autoim-
mune disease onset, remain poorly defined.
Notch receptors form a family of evolutionarily con-
served transmembrane receptors that play crucial roles
in binary cell fate decisions in many developmental sys-
tems (Maillard et al., 2005). Notch1 signaling has been
shown to be determinant during thymic T cell develop-
ment at several major branching points including T ver-
sus B lineage engagement, ab versus gd TCR usage, and
CD4 versus CD8 single-positive T cell differentiation.
Notch1 is also involved in peripheral T cell function,
such as activation, CD25 upregulation, and proliferation
of peripheral mature T cells (Adler et al., 2003; Eagar
et al., 2004), as well as in T helper 1 (Th1)-Th2 differentia-
tion (Amsen et al., 2004; Minter et al., 2005; Radtke
et al., 2004). It has further been reported that Notch3
is expressed at higher amounts on Treg cells than on
CD4+CD252 cells, resulting in enhanced Treg cells gen-
eration in mice transgenic for the cleaved intracellular
active Notch3 (Anastasi et al., 2003). A role of Notch
and its ligands in the development or functional mainte-
nance of Treg cells was further suggested by the evi-
dence for differential transcription of Deltex, which facil-
itates Notch signaling, in human CD4+CD25+ T cells. It is
also consistent with anti-CD3 and anti-CD28-induced
upregulation in Treg cells of the transcription of Notch4
and Delta1, as well as of Hes-1, the downstream media-
tor of Notch signaling (Ng et al., 2001). Additionally, over-
expression of a transgene encoding the human Notch
ligand Jagged1 in antigen-presenting cells (APC) pro-
moted the development of IL-10-producing regulatory
T cells (Tr1) in humans (Vigouroux et al., 2003) and of im-
munosuppressive CD4 T cells that mediated active anti-
gen-specific tolerance in vivo in mice (Hoyne et al., 2000).
However, cellular interactions resulting in Treg cell ex-
pansion through Notch signaling in nontransgenic, phys-
iological, or pathophysiological settings remain to be
defined.
We hypothesized that events or factors triggering he-
matopoiesis might set off Notch-mediated Treg cell ex-
pansion. Indeed, the Notch signaling pathway is also
involved in hematopoietic stem cell decisions at the crit-
ical checkpoint between self-renewal and commitment
into multiple lineages. Diverse Notch receptors and li-
gands have been detected on early multipotent hemato-
poietic progenitors and on bone marrow stroma (Dun-
can et al., 2005; Radtke et al., 2004). Human bone
marrow cells enriched for hematopoietic stem cells
(HSCs) engraft at higher rates in vivo when cultured in
the presence of the Notch1 ligand Jagged1 (Karanu
et al., 2000). The Notch ligand Jagged2, in particular, is
expressed on early murine hematopoietic progenitors
and has been shown to promote their survival and
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824Figure 1. Autologous HPC Transplantation in NOD Mice Prevents Spontaneous Diabetes
(A) Sublethally (800 cGy) irradiated (Irr) NOD CD45.1+ mice were injected i.v. with 104 HPCs from NOD CD45.2+ donors at 6 weeks of age (n = 8
mice per group) and monitored for 27 weeks for diabetes incidence. p = 0.0074, HPC recipients compared to control NOD mice, and p = 0.0025
when compared to irradiated NOD mice. Diabetes incidence did not differ significantly in irradiated or nonirradiated untreated mice and in HSC
(2.5 3 104) recipients. Data are representative of three independent experiments.
(B) Insulitis was scored (see Experimental Procedures) in pancreata removed at 25 weeks of age from HPC NOD recipients, and in 6- and
25-week-old untreated NOD controls (means 6 SEM from 4 organs per group).*p < 0.05, HPC recipients compared to 25-week-old controls.
(C) Irradiated (800 cGy) 16-week-old NOD CD45.1+ mice (n = 8 mice per group) were either untreated or injected with 5000 NOD CD45.2 HPCs and
monitored for diabetes. p = 0.0472.proliferation (Tsai et al., 2000). We have previously dem-
onstrated that the hematopoietic growth factor G-CSF
can prevent type 1 diabetes in nonobese diabetic
(NOD) mice by triggering the recruitment of Treg cells
(Kared et al., 2005). Even though we established that
dendritic cells (DCs) could recruit Treg cells in these
conditions, a direct effect of G-CSF-mobilized hemato-
poietic progenitors on Treg cell emergence or expan-
sion could not be excluded. Here we provide evidence
that Lin2Sca-1+c-kit+ (LSK)-hematopoietic progenitors
(HPCs) mobilized by a synergistic cocktail of G-CSF
and Flt3 ligand (Flt3-L) are enriched in a Jagged2+ sub-
set, as compared with medullary LSK-HSCs. Once
sorted, these cells could expand Treg cells via the Notch
signaling pathway and thereby halt disease onset in the
NOD mouse model of type 1 diabetes, whereas their
Jagged22 LSK-HPC counterpart, Jagged2 siRNA-
knocked-down LSK-HPCs and the Jagged2lo medullary
LSK-HSCs, had no such effect.
Results
Adoptive Transfer of Mobilized HPCs Prevents
Spontaneous Diabetes
LSK cells were electronically sorted from the bone mar-
row of control mice (HSCs) or from the spleen of mice
mobilized with the cytokines G-CSF and Flt3-L (HPCs).
We used congenic CD45.1 and CD45.2 mice to track
transplanted LSK cells in the NOD mouse model of spon-
taneous autoimmune diabetes. A single inoculation of
mobilized HPCs (as few as 104 sorted LSK cells/mouse)
from NOD-CD45.2+ congenic mice into sublethally ir-
radiated 6-week-old NOD-CD45.1+ female recipients
significantly decreased the incidence of spontaneous
diabetes (Figure 1A). HPCs (33 104) derived from NOD-
Rag22/2 mice conferred the same degree of protection
(data not shown), whereas administration of 2.5 3 104
bone marrow (BM)-derived HSCs had no such effect.
The sublethal irradiation required for progenitor engraft-
ment did not modify the disease incidence per se. Pro-
tected HPC recipients developed limited insulitis ascompared to controls (Figure 1B). As few as 5000 HPCs
administered just before diabetes onset, at 16 weeks
of age, protected 83% of recipients after 10 weeks and
50% as late as 16 weeks after transfer (Figure 1C). These
data support the conclusion that only mobilized hemato-
poietic progenitors provide protection against disease,
even at late stages.
The Frequency of Functional Treg Cells Is Increased
in PLN of HPC Recipients
Spleens and peripancreatic lymph nodes (PLN) of 25-
week-old protected HPC recipients contained on aver-
age 3 and 4 times more CD4+CD25+Foxp3+ T cells, re-
spectively, than unprotected recipients having received
HPCs or HSCs and age-matched irradiated or nonirradi-
ated diabetic animals. CD4+CD25+Foxp3+ T cell counts
in protected HPC recipients were increased approxi-
mately 2-fold over those of 6-week-old NOD controls
(Figure 2A). The expansion of Treg cells took place in
NOD recipients whether they were injected with mobi-
lized HPCs from congenic CD45.2+-NOD mice or NOD-
Rag22/2 mice (data not shown), indicating that the
vast majority (80%–90%) of expanded CD4+CD25+ T
cells were of recipient origin, as confirmed by FACS
analysis (Figure 2B).
The expression of the transcription factor Foxp3, typ-
ically associated with the suppressive activity of Treg
cells (Hori et al., 2003), was higher among gated
CD4+CD25+ PLN cells from protected HPC recipients
than among their counterpart from recent diabetic mice
(Figure 2C). Membrane-bound TGF-b1 (see Figure S1B
in the Supplemental Data available online), which is
known for its capacity to maintain the suppressor func-
tion and Foxp3 expression in CD4+CD25+ regulatory T
cells (Marie et al., 2005), was likewise expressed at higher
amounts. Accumulating CD4+CD25+Foxp3+ cells were
sorted from spleens of protected HPC recipients to as-
sess their functions. They suppressed the proliferation
of freshly prepared splenic CD4+CD252 control cells
(Figure 2D) at various CD25+:CD252 cell ratios, nearly
as efficiently as CD4+CD25+ cells from 6-week-old
HPCs Expand Treg Cells through Notch Signaling
825Figure 2. CD4+CD25+ Regulatory T Cells Are Increased in HPC-Protected NOD Recipients
(A) CD4+CD25+Foxp3+ T cell counts in PLN and spleen from 25-week-old HPC-protected (HPC prot) and diabetic (HPC dia) recipients, HSC
recipients, untreated diabetic mice, and 6-week-old controls (means 6 SEM, 3–7 determinants per group); *p < 0.02 in PLN, p < 0.03 in spleen.
(B) Proportion of CD45.2 cells within gated CD4+CD25+ PLN cells in 25-week-old protected HPC recipients. The numbers indicate percent of
cells within the gate.
(C) FACS analysis of Foxp3 expression in PLN CD4+CD25+ gated cells from HPC recipients, as compared to recent diabetic mice. Staining of
CD4+CD252 cells from HPC recipients and of CD25+ cells with an isotype control are shown in dotted lines.
(D) Suppressive properties of CD4+CD25+ cells from HPC recipients and 6-week-old controls over control CD4+CD252 cells activated with
2.5 mg/ml anti-CD3, at various CD25+:CD252 ratios (means 6 SEM of quadruplicate wells).
(E) Adoptive cotransfer of diabetogenic splenocytes (3 3 106) into NOD-SCID recipients (n = 6 per group), either alone or together with
CD4+CD25+ cells (5 3 104 cells) (p% 0.0012) isolated from PLN of HPC recipients.
(F) Adoptive transfer of diabetogenic splenocytes from recent diabetic NOD donors (3 3 106) into NOD-SCID recipients (n = 6 per group) or of
sorted CD252 spleen cells (1.5 3 106 cells) isolated from HPC recipients.
(G) Sublethally irradiated 6-week-oldCd282/2NOD mice were transplanted with 33 104 HPCs or left untreated (n = 8 mice per group). p = 0.0085.
Incidence of diabetes was identical in irradiated and nonirradiated untreated mice (data not shown). Data are from one representative experiment
out of two in (E)–(G).control NOD mice, whereas they hardly proliferated on
their own in vitro. In vivo, as few as 5 3 104 CD25+ PLN
cells significantly protected against 33 106 splenocytes
from untreated diabetic NOD mice cotransferred into
secondary NOD-SCID recipients (Figure 2E). Spleno-
cytes from protected HPC recipients could transfer the
disease to NOD-SCID secondary recipients once theyhad been depleted for CD25+ cells, thus confirming the
protective functions of the Treg cell population. Indeed,
when 1.5 3 106 sorted CD252 spleen cells derived from
HPC recipients were administered to NOD-SCID sec-
ondary recipients, diabetes occurred in 50% of treated
mice within 6 weeks and in 100% within 8 weeks (Fig-
ure 2F). This implies that diabetogenic effectors persist
Immunity
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efficiently controlled by expanded Treg cells in HPC re-
cipients, through active tolerance. Yet, the pathogenic
potential of persisting CD252 diabetogenic effectors
was somewhat reduced, as shown by the delayed onset
of diabetes after transfer into secondary NOD-SCID
recipients. Furthermore, their IFN-g production was di-
minished (Figure S1), even though they did not become
Foxp3+ (Figure 2C).
HPCs Promote the Expansion of Peripheral
Adaptive Treg Cells
We addressed the question of the origin of expanded
Treg cells by grafting mobilized HPCs into sublethally
irradiated Cd282/2 NOD recipients, in which natural
thymus-derived Treg cells (Salomon et al., 2000; Tang
et al., 2004) cannot be maintained because of the lack
of costimulatory signals. HPCs prevented diabetes on-
set very efficiently in these mice (Figure 2G). Further-
more, functional CD4+CD25+ cells accumulated in the
PLN of Cd282/2 NOD mice, similarly to their wild-type
NOD counterpart (Figure S2). These results suggest
that HPCs promote the expansion of peripheral adaptive
rather than thymic Treg cells, which does not exclude
a possible partial peripheral conversion of autoreactive
effectors into regulatory T cells.
HPCs Promote Functional Treg Cell
Expansion In Vivo
We took advantage of the adoptive diabetes transfer
model to assess whether mobilized HPCs exerted a di-
rect growth-promoting activity on Treg cells and main-
tained their suppressive functions without affecting
effector cells directly. Mobilized HPCs (53 104 cells) pu-
rified from the spleen of NOD-Rag22/2 donors, which
failed to differentiate into mature T cells, did not prevent
diabetes when sorted CD252 cells (3 3 106) from the
spleen of recent diabetic NOD mice were transferred
into sublethally irradiated NOD-Rag 22/2 recipients. In
contrast, they provided an effective protection when co-
injected with only 1 3 105 sorted CD4+CD25+ Treg cells
(Figure 3A), which were unable to prevent diabetes
transfer at such low numbers (106 Treg cells would be re-
quired to do so; data not shown). It should be noted that
the same number of HSCs (53 104) purified from the BM
provided no protection when cotransferred with both
diabetogenic T cells and Treg cells (data not shown).
To examine whether disease protection resulted
from homeostatic expansion of the limited number of
inoculated Treg cells, we used the CD45.2 marker to
track these cells in the cotransfer model. Sublethally
irradiated NOD-Rag22/2 mice were coinjected with
sorted CD45.1+CD252 diabetogenic splenocytes and
CD4+CD25+ cells (105 or 106) from CD45.2 NOD donors,
with or without HPCs (5 3 104) from NOD-Rag22/2
donors. Treg cells (Figure 3B) were clearly increased
at 48 days after transfer, when the number of
CD4+Foxp3+CD45.2+ cells—all of them CD25+—in the
PLN was 2- to 7-fold higher in mice coinjected with
HPCs + Treg cells (105 CD4+CD25+ cells) than in mice
coinjected only with 106 or 105 Treg cells, respectively.
Hence, HPCs alone do not impair diabetes transfer by
CD25-depleted splenocytes but induce efficient in vivo
expansion of cotransferred Treg cells.HPCs Promote Direct and Selective Proliferation
of Treg Cells In Vitro
When NOD-Rag22/2-derived HPCs cocultured with
CD4+CD25+ cells (initial ratio 1:1) were stimulated with
anti-CD3 + anti-CD28-coated microbeads instead of
APCs, CD4+CD25+ initial cell counts were consistently
increased 7-, 18-, and 30-fold after 7, 14, and 37 days of
coculture, respectively (Figure 4A). These CD4+CD25+
cells upregulated their Foxp3 expression (Figure 4B)
and their suppressive effect on CD4+CD252 proliferation
was enhanced, their inhibitory index being 4-fold higher
(at a CD25+:CD252 ratio of 1:16) than that of Treg cells
cultured in the absence of HPCs (Figure 4C). Further-
more, they diminished the proliferation of CD4+CD252
cells in the presence of APCs from 20,779 6 2,699
Figure 3. HPCs Synergize with and Drive In Vivo Expansion of Treg
Cells to Prevent Diabetes Cotransfer in NOD-Rag22/2 Mice
(A) Sublethally irradiated NOD-Rag22/2 mice (n = 10–12 per group)
were transferred with sorted CD252 diabetogenic splenocytes (3
3 106) alone or in association with HPCs (5 3 104, NS), with
CD4+CD25+ cells (1 3 105, NS), or with both HPCs (3 3 104) and
CD4+CD25+ cells (1 3 105) (p = 0.046). One representative experi-
ment out of two is shown.
(B) CD4+Foxp3+CD45.2+ cell counts were measured in spleen and
PLN at days 15 and 48 after transplant in mice (3–5 per group)
injected with sorted CD45.1+CD252 diabetogenic splenocytes (3 3
106) together with CD45.2+CD4+CD25+ cells (1 3 105, or 1 3 106)
or with a mixture of CD45.2+CD4+CD25+ cells (1 3 105) and NOD-
Rag22/2 HPCs (5 3 104). Data are expressed as mean 6 SEM.
*p = 0.0373.
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(A) Isolated CD4+CD25+Foxp3+ T cells were cocultured over 7, 14, and 37 days in the presence or the absence of HPCs at a 1:1 ratio (13 105 cells
of each subset) without APCs and in presence of anti-CD3 + anti-CD28-coated microbeads (8 beads/cell), at 10 ng/ml IL-2, and the increase of
CD4+CD25+Foxp3+ cell number was calculated (data expressed as mean 6 SEM of triplicate determinations).
(B) Foxp3 expression was analyzed by FACS on sorted CD4+CD25+ cells either freshly isolated or after 37 days of culture as in (A).
(C) Treg cells cultured as in (A) with or without HPCs were collected, washed, and subsequently cocultured over 72 hr with fresh CD4+CD252 cells
at various CD25+:CD252 cell ratios with 2.5 mg/ml anti-CD3. Their activity was expressed as percent inhibition, calculated as the ratio [(a2 b)/a]3
100, where a and b stand for c.p.m. of 3H-TdR incorporation obtained in quadruplicate wells (mean 6 SEM) containing CD4+CD252 cells and
CD4+CD252 cells + Treg cells, respectively.
(D) Sorted CD4+CD25+ T cells were cocultured for 96 hr with or without HSCs or HPCs at a 1:1 ratio in presence of APCs (2.53 104 cells of each
subset) and soluble anti-CD3 (10 mg/ml), with or without neutralizing TGF-b or control antibodies (20 mg/ml). Proliferation was measured by 3H-
TdR incorporation within the last 8 hr. The stimulation index was calculated as the ratio of c.p.m. in wells [a2 b]/b, where a and b stand for (CD25+
+ HPCs + APCs) and (CD25+ + APCs), respectively. HSCs or HPCs cultured with APCs did not proliferate in response to anti-CD3 (unpublished
data).
(E) Coculture was performed in transwell plates in the presence of anti-CD3 (10 mg/ml), during 96 hr, with 105 cells/1 ml/well of each cell subset,
separated or not by the transwell membrane, with HPCs and APCs in the upper chamber, CD4+CD25+ cells and APCs in the lower chamber.
Proliferation was measured as in (D).c.p.m. to 11,173 6 2,122 c.p.m. (mean 6 SEM). HPCs
also increased 3H-TdR incorporation by Treg cells stim-
ulated with anti-CD3 and cocultured for 96 hr with APCs,
25- to 35-fold, as compared with a 3-fold increase in the
presence of HSCs (Figure 4D). Thus, HPCs directly stim-
ulate the in vitro expansion of TCR-activated functional
Treg cells, without necessarily involving APCs.
HPCs Stimulate Cell Contact-Dependent
Treg Cell Proliferation
Addressing the question of whether cell-contact and/or
soluble factor(s) were required for HPC-induced Treg
cell expansion, we examined the role of TGF-b, which
has been reported for its capacity to promote peripheral
Treg cell expansion (Marie et al., 2005). To this end, we
evaluated the effect of a specific neutralizing TGF-b anti-
body on HPC-induced 3H-TdR incorporation by Tregcells (Figure 4D). This treatment had no significant effect
in accordance with the lack of TGF-b production by
HPCs or HSCs (data not shown), measured by intracel-
lular FACS analysis, as in Figure S1. Instead, the prolifer-
ation of CD4+CD25+ cells induced by HPCs was reduced
by two-thirds when cell-to-cell contact was prevented in
transwell cultures (Figure 4E) with Treg cells in the lower
and HPCs in the upper chamber, both containing irradi-
ated APCs. It can therefore be concluded that direct
cell-to-cell contact is essential for the stimulation of
Treg cell expansion by HPCs.
HPCs Stimulate Treg Cell Proliferation by Activating
the Notch Signaling Pathway
It has been established that binding of any molecule of
the Notch family (Notch1–4) of transmembrane recep-
tors to a ligand on a neighboring cell initiates proteolytic
Immunity
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quires Notch Signaling
(A) Sorted CD4+CD25+ T cells were cocul-
tured for 96 hr with or without HPCs at a 1:1
ratio in presence of APCs (2.5 3 104 cells of
each subset) and soluble anti-CD3 (10 mg/
ml), and/or various concentrations of the g
secretase inhibitor (GSI 2, 5, 10 mM) or equiv-
alent volume of its vehicle DMSO for the
higher GSI dose, or Jagged2 and Notch3 (1
and 2 mg/ml), or control rabbit (2 mg/ml) anti-
bodies. Proliferation was measured and the
stimulation index calculated as in Figure 4D.
Data are expressed as stimulation indexes obtained in one representative experiment out of three, performed in quadruplicates.
(B) Notch3 expression was measured on sorted CD4+CD25+ cells, freshly isolated (mean fluorescence intensity, MFI = 21), or cocultured for 96 hr
without APCs, in the presence of anti-CD3 (10 mg/ml) and anti-CD28 (5 mg/ml), with (MFI = 25) or without (MFI = 237) HPCs (ratio 1:1). For negative
controls (dotted line), the primary rabbit antibody was omitted. Results shown are representative of three independent experiments.cleavage by a preselinin-associated g-secretase of the
intracellular portion of Notch (Notch IC), which then
translocates to the nucleus, where it indirectly activates
transcription (Radtke et al., 2004). Therefore, we
used a g-secretase inhibitor (Mizutani et al., 2001)
(GSI) (S-2188, Sigma-Aldrich, St. Louis, MO) to assess
how Notch-NotchL interactions could account for the
growth-promoting effect of HPCs on Treg cells. GSI
abrogated HPC-induced 3H-TdR incorporation (and cell
expansion, data not shown) of Treg cells at various con-
centrations ranging from 2 to 10 mM, whereas DMSO
vehicle at the highest dose had no effect (Figure 5A).
The growth of CD252 cells was not impaired by GSI
[(9.47 6 0.13) 3 106 cells with GSI versus (10.2 6
1.03) 3 106 cells without GSI], showing that it exerted
no general antiproliferative action. Furthermore, it had
no effect per se on CD25+ cells and did not alter cell sur-
vival, as assessed by PI staining of Treg cells cocultured
with HPCs (data not shown).
Both Jagged2 and Notch3 antibodies inhibited Treg
cell expansion measured by 3H-TdR incorporation (Fig-
ure 5A) and cell numbers (data not shown), underscoring
the functional relevance of the NotchL-Notch receptor
interactions. Furthermore, in accordance with a direct
stimulation, Notch3 expression was notably increased
on Treg cells upon incubation with HPCs (Figure 5B).
These findings reveal the importance of Notch signaling
for the expansion of Treg cells by HPCs, which appears
to result mainly from interactions between Notch3 re-
ceptors in Treg cells and Jagged2 on HPCs.
LSK HPCs Are Enriched in Jagged2+ Multipotent
Progenitors
Based on our evidence for the requirement of Jagged2
during Treg cell expansion, we examined how this ligand
was distributed among hematopoietic progenitor cells.
The small LSK compartment in adult mice comprises
the majority of progenitors with long-term and short-
term reconstituting potential (LT-HSCs and ST-HSCs,
respectively) as well as the multipotent progenitor pop-
ulation (MPP). When LSK-HPCs were isolated from the
spleen after mobilization with G-CSF and Flt3-L, their
numbers were drastically reduced in the bone marrow.
Such LSK-HPCs comprised at least 2-fold more cells ex-
pressing Jagged2 than the nonmobilized bone marrow
HSCs (Figure 6A). Thus, after sorting, approximately
70% HPCs were Jagged2+ and coexpressed Flt3 recep-tor, CD34, and CD106 (VCAM-1) but not CD127 (data not
shown), the IL-7Ra chain expressed on the common
lymphoid progenitors (CLP) (Figure 6B; Kondo et al.,
1997). In contrast, HSCs were essentially Jagged2lo,
CD106+, but like Jagged22 HPCs, they did not express
Flt3, CD34, or CD127 (Figure 6C). Notably, LSK cells in
spleens of nonmobilized animals represented only
0.7% of Lin2 spleen cells, approximately 0.02% of total
spleen cells, whereas LSK cells represented 2% to 5%
of total spleen cells in mobilized animals. They exhibited
a Lin2c-kit+Sca-1+CD34+Flt3+ phenotype, of which only
10% expressed Jagged2 at low amounts (data not
shown). Both medullary HSCs and mobilized HPCs
gave rise to myeloid as well as lymphoid colonies in
methylcellulose assays (data not shown) (Kondo et al.,
1997), and effective multilineage hematopoietic micro-
chimerism could be achieved in sublethally irradiated re-
cipients with all medullary and spleen progenitor sub-
sets tested (Figure 6D). Altogether, these data indicate
that HSCs share the phenotype reported for LT-HSCs
and/or ST-HSCs, whereas Jagged2+-HPCs represent
VCAM-1+-MPP that have reached a differentiation stage
situated before the branching point between the Sca-
1loVCAM-1+ common myeloid progenitors (CMP) and
a recently identified VCAM-12MPP subset, which might
give rise to the VCAM-12CD127+ CLP (Adolfsson et al.,
2001; Christensen and Weissman, 2001; Lai et al.,
2005; Reya et al., 2001).
Only Jagged2+ HPCs Promote Treg Cell Expansion
A detailed kinetic analysis revealed that total HPCs typ-
ically triggered CD4+CD25+Foxp3+ cell expansion in
PLN of transplanted NOD recipients within the first 30
days after transfer (Figure 7A), whereas HSCs were un-
able to promote Treg cell expansion in vivo (Figure 7B)
as previously observed in vitro. The role of Jagged2 in
Treg cell expansion by HPCs was supported by the fol-
lowing indications. (1) There was effective Jagged2
knockdown in HPCs by specific siRNA but not by the
control construct, which downregulated Jagged2 ex-
pression to HSC amounts (Figure 7C). This manipulation
abolished the capacity of HPCs to trigger Treg cell accu-
mulation in vivo (Figure 7B). (2) There were increased
Treg cell counts in PLN exclusively in response to elec-
tronically sorted Jagged2+ HPCs (Figure 7C). (3) There
was selective protection against diabetes upon trans-
plantation of the Jagged2+ HPCs into NOD recipients
HPCs Expand Treg Cells through Notch Signaling
829Figure 6. Phenotype and Differentiation Potential of Progenitor Subsets
(A) Jagged2 expression was measured by FACS among gated Sca-1+c-kit+ HSCs and HPCs. Of note, LSK-HSCs in the NOD mouse displayed
lower Sca-1 expression than in the C57BL/6 mouse strain.
(B) LSK-HPCs were sorted into Jagged2+ and Jagged22 fractions, which were compared with HSCs in (C) for their expression of CD34, Flt3, and
CD106.
(D) Multipotent differentiation of HPC subsets and HSCs in sublethally irradiated NOD recipients. Chimerism was assessed in peripheral blood
and spleens collected from HPC and HSC recipients (n = 3 mice per group), 30 days after grafting of 2.53 104 HSCs or total HPCs, 13 104 Jag-
ged2+ or Jagged22 HPCs. Proportions of CD45.2 cells (mean 6 SEM) within different cell subsets were analyzed by FACS. N.S. HSCs injected
alone or together with recipient total BM cells gave similar microchimerism (data not shown).(Figure 7D). Thus, Jagged2 expression within HPCs is
directly responsible for their capacity to stimulate Treg
cell expansion in vivo and to prevent disease.
Discussion
In this study, we provide evidence for a productive
Notch-mediated interaction between a unique subset
of mobilized hematopoietic progenitors and Treg cells.
We demonstrate that progenitors sharing the phenotyp-
ical features of VCAM-1+ MPP and expressing the Notch
ligand Jagged2 can interact directly with Treg cells and
promote their expansion. The host-derived Foxp3+ Tregcells conferred active tolerance against pathogenic
effector cells, which persisted in protected HPC
recipients.
Conversely, we confirmed that freshly isolated medul-
lary HSCs promoted neither Treg cell expansion nor dis-
ease protection (Beilhack et al., 2003; Steptoe et al.,
2003). Importantly, protective or nonprotective LSK pro-
genitor subsets or HSCs gave rise to similar multipotent
microchimerism both in terms of quality and quantity,
suggesting that HPC progeny was not responsible for
protection. NOD-Rag22/2-derived HPCs were equally
effective, ruling out the participation of lymphoid HPC
descendants. The involvement of HPC-derived myeloid
Immunity
830Figure 7. Treg Cell Expansion In Vivo by HPCs Requires Jagged2 Expression
(A) NOD mice (6-week-old, 3–5 mice per group) were sublethally irradiated only and/or injected with 2.5 3 104 CD45.2+ HPCs, and
CD4+CD25+Foxp3+ T cell counts were monitored in the PLN of individual mice by FACS and expressed as mean 6 SEM.
(B) CD4+CD25+Foxp3+ cells were enumerated in the PLN of either 6-week-old NOD mice (n = 5–10 mice per group) either untreated or 30 days
after sublethal irradiation with or without transfer of either total LSK-HPCs (2.53 104 cells/mouse), sorted Jagged22 and Jagged2+ (13 104 cells/
mouse) LSK-HPC fractions, HPCs transfected with either Jagged2 siRNA, or control construct or HSCs (2.5 3 104 cells/mouse). p < 0.001, dif-
ferences between groups.
(C) Jagged2 expression was analyzed by FACS in HPCs 72 hr after transfection with either Jagged2 siRNA or control construct, and compared
with HSCs.
(D) Diabetes incidence in sublethally irradiated 6-week-old NOD mice, transplanted with either Jagged22 or Jagged2+ HPCs (1 3 104 cells). p =
0.0118.cells in promoting Treg cell expansion was also unlikely,
because of the similar proportion of the CD11c and
PDCA-1 subtypes among the DC progeny of HSCs or
HPCs. Mobilized HPCs were clearly more immature
than the CD11bhiGr-1lo myeloid precursors, which
have been shown to give rise to resting DCs and sup-
press autoimmune diabetes (Steptoe et al., 2005). Fur-
thermore, compared to HPCs, 100-fold more GM pre-
cursors were required to prevent diabetes, through
mechanisms that did not depend on Treg cells but on
the expression of the autoantigen proinsulin as a trans-
gene. With allogeneic models of GVHD, it was demon-
strated (MacDonald et al., 2005) that nontransgenic
GM precursors differentiating into CD402 APCs accu-
mulated in response to treatment with a synthetic G-
CSF-Flt3L molecule and promoted tolerance through
IL-10-producing, antigen-specific suppressive
CD4+CD25+ cells that have not been analyzed for
Foxp3 expression. We detected no significant accumu-
lation of CD11bhiGr-1lo myeloid precursors within our
HPC progeny or within the endogenous recipient im-
mune system (data not shown). Although we cannot
eliminate a possible qualitative difference betweenHPC and HSC descendants, a strong indication that
HPCs exert a direct, immediate protective role is pro-
vided by the kinetics of Treg cell expansion, which was
detectable as early as day 7, when progenitor differenti-
ation was not complete. Moreover, it turned out that
knockdown of Jagged2 by HPCs with siRNA technology
effectively abrogated Treg cell expansion, which is not
consistent with the involvement of HPC progeny be-
cause of the transient blockade of Jagged2 expression.
Nevertheless, it is possible that HPC descendants par-
ticipate in long-term maintenance of tolerance in HPC
recipients.
Direct cell-to-cell contact was essential for the
growth-promoting effect of HPCs on Treg cells even
though a contribution of soluble factor(s) cannot be ex-
cluded because Treg cell proliferation was not com-
pletely abolished by the transwell membrane. TGF-b
maintains peripheral Treg cells (Marie et al., 2005), and
membrane-bound TGF-b on Treg cells interacts with
Notch receptors on effector T cells to exert suppression
(Ostroukhova et al., 2006). However, neither HPCs nor
HSCs produced TGF-b, and neutralization of TGF-b
did not impair Treg cell expansion by HPCs. Thus, the
HPCs Expand Treg Cells through Notch Signaling
831soluble factor that mediates HPC-induced Treg cell
expansion and is not produced by HSCs is definitely
distinct from TGF-b but has not been clearly identified
so far.
The involvement of the Notch signaling pathway in
contact-dependent Treg cell expansion promoted by
HPCs was supported by several data, namely its abroga-
tion by a specific g-secretase inhibitor and by either Jag-
ged2 or Notch3 antibodies as well as by the upregulation
of Notch3 expression on Treg cells during coculture. It
was confirmed by the observation that sorted Jagged2+
HPCs were the only LSK-HPC subpopulation to promote
Treg cell expansion in PLN of recipients and to provide
protection against spontaneous diabetes. In further sup-
port, selective Jagged2 knockdown in HPCs by siRNA,
which reduced Jagged2 expression to levels similar to
those of HSCs, abrogated their capacity to trigger Treg
cell accumulation in vivo. Furthermore, HPCs displayed
more Jagged2 than HSCs, whereas Jagged1 was unde-
tectable (unpublished data).
Interestingly, BM-derived DCs (Amsen et al., 2004)
also express Jagged2 at levels that can be upregulated
by pro-Th2 stimuli, such as cholera toxin and PGE2
(Amsen et al., 2004). To our knowledge, involvement of
Notch signaling in their capacity to promote Treg cell ex-
pansion (Tarbell et al., 2004; Yamazaki et al., 2003) has
not been evaluated. The question of whether central
Treg cell development involves Jagged2 expression by
thymic epithelial cells (Anderson et al., 2001) or by
thymic DCs deserves further investigation.
Whereas previous data demonstrated that transgenic
enhancement of the expression either of a Notch ligand
(Vigouroux et al., 2003) on a cellular partner of Treg cells
or of a Notch receptor on Treg cells themselves (Anas-
tasi et al., 2003) could lead to Treg cell emergence,
here we show that physiological stimulation of hemato-
poiesis effectively activates Notch signaling by a selec-
tive progenitor subset that favors expansion of Treg
cells with therapeutic consequences. In the normal,
nonautoimmune animal, infectious diseases have been
reported to trigger splenic hematopoiesis as an endog-
enous response associated with increased G-CSF pro-
duction (Murray et al., 1998), which, in turn, might lead
to enhanced generation of mobilized tolerogenic pro-
genitors.
Several features of Treg cell expansion by autologous
transplantation of HPCs are encouraging for future clin-
ical applications. It is noteworthy that the relatively mod-
est Treg cell expansion in vitro ensured nevertheless
a durable protection in vivo and did not lead to leukemic
T cell expansion, as might be feared from Notch stimu-
lation (Reya et al., 2001). Treg cell numbers were main-
tained for 1 to 4 months after HPC transplantation within
physiological proportions, e.g., twice as much as those
encountered in young 6-week-old nondiabetic NOD
mice. These data further suggest that Treg cell numbers
need not be massively expanded, provided that they are
functional and migrate adequately to PLN, offering pro-
tection against pathogenic effectors. Interestingly, dis-
ease remission by autologous hematopoietic stem cell
transplantation (ASCT) performed in patients with juve-
nile inflammatory arthritis was very recently described
(de Kleer et al., 2006) to proceed through the restoration
from severely reduced to normal levels of Treg cellnumbers (ranging from 1.3- to 6.5-fold compared to
baseline levels before ASCT), together with immune de-
viation of autoimmune cells.
The protection against diabetes afforded by HPCs
even at late phases before disease onset further argues
in favor of HPC transplantation in patients in whom dis-
ease is usually detected late in the autoreactive process.
G-CSF (Welte et al., 1996) and Flt3-L (Higano et al., 2004)
are well tolerated in the clinics, and G-CSF is commonly
used for mobilization into and harvest of hematopoietic
progenitors from the peripheral blood in patients. Al-
though we and others (Chilton et al., 2004; Hadaya
et al., 2005; Kared et al., 2005; O’Keeffe et al., 2005)
have shown in the NOD mouse that G-CSF or Flt-3L
could prevent diabetes onset, neither factor on their
own was able to provide significant protection if treat-
ment was started after 6 weeks of age. In our hands,
treatment of 16-week-old NOD mice with a mixture of
G-CSF and Flt3-L, using the same dose and length of
treatment as for mobilization, did not prevent diabetes
(data not shown). Therefore, cell therapy with the sorted
tolerogenic HPC subset may convey protection (leaving
50% mice disease-free at 30 weeks of age) at a stage of
diabetes development at which G-CSF and/or other
factors are no longer efficient. Interestingly, effective
protection by autologous HPCs required only minimal
myelosuppressive conditioning for engraftment.
Our data obtained in the NOD mouse model suggest
that adult mobilized autologous HPCs, and singularly
their sorted Jagged2+ subset, might improve cell ther-
apy relative to nonmobilized syngeneic HSCs that have
intrinsic autoimmune potential (Serreze et al., 1988),
and to the effective, yet high-risk, allogeneic transplan-
tation (Beilhack et al., 2003), in patients with severe au-
toimmune diseases (Burt et al., 2002; de Kleer et al.,
2006) as well as in several other clinical settings requir-
ing in vivo expansion of Treg cells. Conversely, selective
deletion of the Jagged2+ fraction of HPCs might be rec-
ommended for progenitor transplantation in cancer pa-
tients, to prevent Treg cell expansion, which adversely




Wild-type CD45.1 and congenic CD45.2 NOD mice, NOD-Rag22/2
mice, and NOD-SCID mice were bred in our animal facility under
specific pathogen-free conditions. Cd282/2-NOD were initially pro-
vided by J. Bluestone. Live animal experiments were approved by
Ministe`re de l’Agriculture, de la Peˆche et de l’Alimentation (France).
In Vivo Treatments and HPC Isolation
Control HSCs were purified from bone marrow cells recovered from
tibias and femurs of NOD-Rag22/2 mice (6- to 8-week-old). The mo-
bilized progenitor cells were prepared as follows: CD45.2- or NOD-
Rag22/2mice (6- to 8-week-old) were injected s.c. for 4 consecutive
days with recombinant human G-CSF (200 mg/kg/day) (Neupogen,
provided by Amgen, Neuilly sur Seine, France) + recombinant mu-
rine Flt3-L (20 mg/kg/day) (R&D Systems, Lille, France; AbCys, Paris,
France). Spleen and bone marrow cells recognized by mAbs di-
rected against mature lineage markers (CD4, CD8, CD11b, Gr-1,
CD45R, Ter119) were depleted with anti-rat Ig-coated magnetic
beads (Dynal Biotech Invitrogen, Cergy Pontoise, France). Medullary
and spleen c-kit+Sca-1+ cells were sorted electronically (>95% pu-
rity) with a FACS Vantage cell sorter (Becton Dickinson, Le Pont
de Claix, France). Their myeloid and lymphoid differentiation
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832potential was assessed by the clonogenic methylcellulose assay
(MethoCult, StemCell Technologies, Grenoble, France), according
to Kondo et al. (1997). c-kit+ Jagged2+ and c-kit+ Jagged22 HPC
fractions were also electronically sorted from Lin2Sca-1+c-kit+ mo-
bilized spleen cells.
Spontaneous and Adoptive Cotransfer Model of Diabetes
Female CD45.1 NOD mice were used for studies of spontaneous di-
abetes and irradiated at 8 Gy (via a Faxitron 160 FW X-ray irradiator)
426 hr before cell transfers (i.v.) to facilitate HPC engraftment.
Transferred HPCs were from congenic CD45.2 NOD mice or NOD-
Rag22/2 mice. For adoptive cotransfer, diabetogenic cells (spleno-
cytes pooled from 3–5 recently diabetic NOD mice) were transferred
i.v. in the absence or presence of Treg cells (prepared as detailed be-
low) and/or NOD-Rag22/2-derived mobilized HPCs into sublethally
irradiated (5 Gy) female NOD-SCID or NOD-Rag22/2 recipients (4-
week-old). Mice were screened for glycosuria (Glucotest, Boeh-
ringer-Mannheim, Mannheim, Germany) twice a week and/or glyce-
mia (Haemoglukotest and Reflolux F, Boehringer-Mannheim) and
were considered diabetic when nonfasting blood glucose levels
were >250 mg/dl on two consecutive readings.
Immunohistochemistry
Pancreata were removed, embedded with OCT, and snap-frozen in
liquid nitrogen. For conventional histopathology, serial 3 mm sec-
tions were stained with haematoxylin and eosin to score mononu-
clear cell infiltration as follows: grade 0 = normal islets; grade 1 =
peripheral or focal insulitis (lymphocytes surrounding the islet or
gathered at a pole, covering <50% of the islet surface); grade 2 =
invasive insulitis covering >50% of the islet surface.
Staining of Cells for Flow Cytometry Analysis
To block nonspecific Fc receptor binding, cells (collected from 3–6
pooled mice or from individual mice) were preincubated for 10 min
at room temperature with FcR blocker 2.4G2 Ab. Cells were subse-
quently stained with appropriate Abs: anti-CD4 (clone GK1.5), anti-
CD8 (clone 53-6.7), anti-CD3 (clone 145-2C11), anti-B220 (clone
RA3-6B2), anti-CD19 (clone 1D3), anti-CD25 (clone PC61), anti-
Mac-1/CD11b (clone M1/70), anti-Gr-1 (clone RA3-8C5), anti-
CD11c (clone HL3), anti-c-kit (CD117, clone ACK 45), anti-Sca-1
(anti-Ly6A/E, clone D7), anti-CD45.1 (clone A20), anti-CD45.2 (clone
104), purchased from BD Biosciences. Anti-PDCA-1 was from Milte-
nyi Biotec (Bergish-Gladbach, Germany). To assess Notch3 expres-
sion, we used a Notch3 rabbit polyclonal antibody (clone M-134,
Santa Cruz Biotechnology, Santa Cruz, CA) targeted at an intracellu-
lar portion of the receptor. Treg cells that had been cultured for 96 hr
with either medium, soluble CD3 (10 mg/ml) and CD28 (5 mg/ml) an-
tibodies, and/or HPCs, were collected and labeled with anti-CD4,
fixed, and permeabilized with 0.5% saponin and subsequently
labeled with Notch3 antibody and anti-rabbit FITC-conjugate
(Sigma-Aldrich, L’isle d’Abeau Chesnes, France). Jagged2 expres-
sion was measured on gated Sca-1+c-kit+ HSCs and HPCs, with rab-
bit anti-Jagged2 (clone H-143, Santa Cruz Biotechnology) and anti-
rabbit FITC-conjugate. Foxp3 expression was measured by FACS
analysis as per manufacturer’s instructions (e-Biosciences, San
Diego, CA). Intracytoplasmic expression of IL-10, TGF-b1, IFN-g,
and IL-4 was assessed after stimulation of PLN cells for 5 hr, or
of HSCs and HPCs for 12 hr, with PMA (10 ng/ml) and ionomycin
(500 ng/ml) in the presence of Brefeldin A (2 mg/ml), followed by
permeabilization with saponin and subsequent staining with specific
antibodies including PE-labeled anti-IL-10, anti-IFN-g (clones
JES5-16E3, XMG1.2, respectively, from BD Biosciences) and
FITC-coupled anti-TGF-b1 (2G7, prepared in the laboratory) or iso-
type controls. Membrane expression of TGF-b1 was analyzed
in nonpermeabilized total PLN cells gated on CD4+CD25+ cells,
with FITC-coupled anti-TGF-b1 (2G7) or control IgG2b antibody.
Membrane and intracellular antigen expressions were analyzed
on a FACScalibur cytometer (BD Biosciences) with CellQuest
software.
siRNA Silencing of Jagged2
Jagged2 siRNA (mouse) and control siRNA-A (Santa Cruz Biotech-
nology) were incubated in serum-free RPMI for 10 min at room tem-
perature with Hi-perfect transfection reagent (Quiagen, France) ata final siRNA concentration of 10 nM. Complexes thus formed
were added dropwise onto the cells (105 cells per well in a 24-well
plate in 0.5 ml of RPMI medium containing FCS and antibiotics)
and incubated for 6 hr. Jagged2 expression was assessed by
FACS 24 to 72 hr after transfection.
Proliferation Assays
Spleen CD25+ cells from 6-week-old female NOD mice were posi-
tively enriched with biotinylated CD25 antibody (BD Biosciences)
and streptavidin-coated magnetic beads (MACS) in MS+ columns
(Miltenyi Biotec). The CD25+ recovered cells were stained with anti-
CD4 and CD4+CD25+ cells were electronically sorted (R95% pure).
The CD252 fraction was used for positive selection of the
CD4+CD252 cells (>90% pure) with anti-CD4-coated beads. The re-
maining CD42CD252 spleen cells were irradiated at 50 Gy and
served as APCs. CD4+CD25+ or CD4+CD252 cells were cultured
(2.5 3 104 cells/well) in RPMI 1640 medium supplemented with 5%
FCS (InVitrogen), 1% antibiotics, and b-mercaptoethanol 5 3 1025
M, in 96-well round-bottomed culture plates, in the presence
of APCs. HPCs were added at a 1:1 HPC:CD4+CD25+ or
HPC:CD4+CD252 cell ratio. Cells were stimulated with CD3 mAb
(clone 145-2C11) at 10 mg/ml during 96 hr for CD25+ cells, and at
2.5 mg/ml during 72 hr for CD252 cells. Tritiated thymidine (3H-TdR,
1 mCi/well) was added for the last 8 hr of culture. Cells were harvested
over glass fiber and 3H-TdR incorporation was measured in a b-plate
scintillation counter. The stimulation index was calculated as the
ratio: [cpm (CD25+ + HPCs) 2 cpm (CD25+)]/cpm (CD25+).
To assess whether HPCs triggered Treg cell expansion in vitro,
FACS-sorted CD4+CD25+ cells (1 3 105 cells/well, in 24-well tissue
culture plates) were stimulated with CD3 + CD28 antibody-coated
beads at a ratio of 8 beads per cell, in complete medium supple-
mented with 10 ng/ml rIL-2 (R&D Systems Europe). After various
times of culture, beads were removed with magnet, and
CD4+CD25+Foxp3+ cells were enumerated by flow cytometry.
Statistical Analysis
Data were analyzed with nonparametric Mann Whitney or ANOVA
(multigroup comparison) test and Kaplan-Meier estimates and log-
rank analysis for diabetes incidence curves. p values <0.05 were
considered statistically significant.
Supplemental Data
Two Supplemental Figures can be found with this article online at
http://www.immunity.com/cgi/content/full/25/5/823/DC1/.
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